- The company anticipates hosting a webcast to discuss the preliminary data on Monday, November 10, at 8:00 AM EST / 2:00 PM CET
- Additionally, the company plans to release its financial results for the third quarter of 2025 pre-market on the identical day
JENA, Germany, Nov. 07, 2025 — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm specializing in anti-inflammatory treatments by targeting the complement system, disclosed today its expectation to unveil preliminary data from the Phase 2a clinical trial of its oral C5aR inhibitor, INF904, in individuals with hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) via a pre-market press release on Monday, November 10, 2025.
InflaRx intends to host a webcast/conference call, complete with a slide presentation, on Monday, November 10, 2025, at 8:00 AM EST / 2:00 PM CET. This event will serve to discuss the preliminary clinical data and incorporate perspectives from key opinion leaders. To join the call, attendees can pre-register to obtain an invitation link and call-in information. The live webcast and an archived audio recording of the presentation will be available on the InflaRx website at https://www.inflarx.de/Home/Investors/Events.html.
Furthermore, the Company is set to publish its financial and operational outcomes for the third quarter of 2025 through a Form 6-K, also pre-market on the identical day.
Pertaining to InflaRx
InflaRx (Nasdaq: IFRX) operates as a biopharmaceutical firm leading the way in anti-inflammatory therapies by utilizing its proprietary anti-C5a and anti-C5aR technologies. This allows them to identify, advance, and market highly effective and precise inhibitors of C5a, a complement activation factor, and its receptor, C5aR. C5a acts as a potent inflammatory mediator implicated in the advancement of numerous inflammatory conditions. InflaRx has created vilobelimab, an innovative, intravenously administered, first-in-class anti-C5a monoclonal antibody. This antibody specifically attaches to free C5a and has shown disease-modifying clinical efficacy and good tolerability across several clinical trials. InflaRx is additionally progressing INF904, an orally administered small molecule designed to inhibit C5a-induced signaling through the C5a receptor.
Established in 2007, InflaRx maintains offices and subsidiaries in Jena and Munich, Germany, along with Ann Arbor, MI, USA. For additional details, kindly visit . InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are entirely owned subsidiaries of InflaRx N.V. (collectively referred to as InflaRx).
Contact Information:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Investor Relations Lead Email: |
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
PROSPECTIVE STATEMENTS
This press release includes statements that are forward-looking in nature. Any statements that are not historical facts are considered forward-looking, frequently identified by words like “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” among others. Prospective statements are present in various sections of this release and may encompass declarations concerning our goals, convictions, forecasts, perspectives, assessments, current projections, and the hazards, ambiguities, and additional elements detailed under the sections “Risk factors” and “Cautionary statement regarding forward looking statements” in our regular filings with the SEC. These declarations are valid only as of the date of this press release and carry inherent known and unknown risks, uncertainties, and other significant considerations that could lead our actual outcomes, performance, or accomplishments to differ substantially from any future results, performance, or achievements explicitly stated or suggested by such forward-looking statements. Given these risks, uncertainties, and other factors, recipients should not unduly depend on these prospective statements, and we disclaim any obligation to revise these forward-looking statements, even if new data emerges subsequently, unless mandated by law.
